Biotricity, a Silicon Valley firm, won FDA clearance for its Bioflux ECG monitoring system. The 3-channel device is used to help spot and identify cardiac arrhythmias. The mobile cardiac telemetry system transmits any likely cardiac events via its built-in 3G/4G cellular connectivity. The triggers can be set and changed remotely by the patient’s cardiologist, allowing for notifications to be programmed for each patient’s unique needs (bradycardia, tachycardia, atrial fibrillation) and diagnostic requirements of the cardiologist. This allows patients to go just about anywhere while being monitored in real time.
A remote center manages the incoming data and provides its own cardiac techs, arrhythmia specialists, and related nurses to advise and assist and provides patient reports, as needed. Cardiologists can use the system themselves and dig in as much as they want to analyze their patient charts.
The device stores up to a month of ECG readings, an impressive feat considering that each heartbeat represents a good deal of data.
Product page: Bioflux…
Via: Biotricity…